Revenio Group Corporation: Revenio Group Corporation will publish its financial statement bulletin for 2019 on Thursday, February 20, 2020

Revenio Group Corporation, Press release, February 5, 2020 at 10.30 a.m.

REVENIO GROUP CORPORATION WILL PUBLISH ITS FINANCIAL STATEMENT BULLETIN FOR 2019 ON THURSDAY, FEBRUARY 20, 2020

Revenio Group Corporation will publish its financial statement bulletin for 2019 on Thursday, February 20, 2020 at approximately 9 a.m. The report will be available after publication at https://www.reveniogroup.fi/en/investors/stock-exchange-releases.

Revenio’s President & CEO Timo Hildén and CFO Robin Pulkkinen will present the report in a live webcast, which can be followed from 9.30 a.m. at https://revenio.videosync.fi/2019-financial-statements/register.

The event will be held in English. Questions will also be taken in Finnish.

A recording of the webcast will be available on Revenio’s website at https://www.reveniogroup.fi/en/investors/audiocast later on the same day.

For further information, please contact:

Robin Pulkkinen, CFO, tel. +358 50 505 9932

The Revenio Group in brief

Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices.

The Revenio Group comprises Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, CenterVue Inc., Revenio Research Oy, and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-led screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The goal is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of the Group is on the early detection of glaucoma, diabetic retinopathy, and macular degeneration, and the monitoring of these during the treatment process. Revenio Research focuses on the commercialization of systems that support the diagnosis of skin cancer and asthma and planning their treatment.

In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.